RU2019113370A - Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения - Google Patents
Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения Download PDFInfo
- Publication number
- RU2019113370A RU2019113370A RU2019113370A RU2019113370A RU2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A RU 2019113370 A RU2019113370 A RU 2019113370A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- seq
- lymphoma
- combination according
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (12)
1. Комбинация, содержащая антитело, специфическое в отношении CD19, где указанное антитело содержит область HCDR1, содержащую последовательность SYVMH (SEQ ID NO: 1), область HCDR2, содержащую последовательность NPYNDG (SEQ ID NO: 2), область HCDR3, содержащую последовательность GTYYYGTRVFDY (SEQ ID NO: 3), область LCDR1, содержащую последовательность RSSKSLQNVNGNTYLY (SEQ ID NO: 4), область LCDR2, содержащую последовательность RMSNLNS (SEQ ID NO: 5), и область LCDR3, содержащую последовательность MQHLEYPIT (SEQ ID NO: 6), и венетоклакс, для применения в лечении неходжкинской лимфомы, хронического лимфоцитарного лейкоза и/или острого лимфобластного лейкоза.
2. Комбинация по п. 1, где антитело характеризуется активностью ADCC.
3. Комбинация по п. 1 или 2, где антитело содержит вариабельный домен тяжелой цепи, содержащий последовательность EVQLVESGGGLVKPGG SLKLSCAASGYTFTSY VMHWVRQAPGKGLEWI GYINPYNDGTKYNEKFQ GRVTISSDKSISTAYMEL SSLRSEDTAMYYCARGT YYYGTRVFDYWGQGT LVTVSS (SEQ ID NO: 10), и вариабельный домен легкой цепи с последовательностью DIVMTQSPATLSLSPGER ATLSCRSSKSLQNVNGN TYLYWFQQKPGQSPQL LIYRMSNLNSGVPDRFS GSGSGTEFTLTISSLEPE DFAVYYCMQHLEYPIT FGAGTKLEIK (SEQ ID NO: 11).
4. Комбинация по любому из предыдущих пунктов, где антитело содержит константный домен тяжелой цепи, содержащий последовательность ASTKGPSVFPLAPSSKS TSGGTAALGCLVKDY FPEPVTVSWNSGALTS GVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQT YICNVNHKPSNTKVD KKVEPKSCDKTHTCP PCPAPELLGGPDVFLF PPKPKDTLMISRTPEV TCVVVDVSHEDPEVQ FNWYVDGVEVHNAK TKPREEQFNSTFRVVS VLTVVHQDWLNGKE YKCKVSNKALPAPEE KTISKTKGQPREPQVY TLPPSREEMTKNQVSL TCLVKGFYPSDIAVE WESNGQPENNYKTTP PMLDSDGSFFLYSKL TVDKSRWQQGNVFS CSVMHEALHNHYTQ KSLSLSPGK(SEQ ID NO: 12).
5. Комбинация по любому из предыдущих пунктов, где антитело содержит константный домен легкой цепи, содержащий последовательность RTVAAPSVFIFPPSDE QLKSGTASVVCLLN NFYPREAKVQWKVD NALQSGNSQESVTEQ DSKDSTYSLSSTLTLS KADYEKHKVYACEV THQGLSSPVT KSFNRGEC (SEQ ID NO: 13).
6. Комбинация по любому из предыдущих пунктов, где указанное антитело, специфическое в отношении CD19, и венетоклакс вводятся отдельно.
7. Комбинация по любому из предыдущих пунктов, где венетоклакс вводится до введения антитела, специфического в отношении CD19.
8. Комбинация по любому из предыдущих пунктов, где указанное антитело, специфическое в отношении CD19, и венетоклакс вводятся одновременно.
9. Комбинация по любому из предыдущих пунктов, где указанное антитело, специфическое в отношении CD19, и венетоклакс вводятся в определенный момент времени, при этом оба лекарственных средства проявляют активность у пациента в одно и то же время.
10. Комбинация по любому из предыдущих пунктов для применения в лечении хронического лимфоцитарного лейкоза.
11. Комбинация по любому из предыдущих пунктов для применения в лечении острого лимфобластного лейкоза.
12. Комбинация по любому из предыдущих пунктов для применения в лечении неходжкинской лимфомы, где неходжкинская лимфома выбрана из группы, состоящей из фолликулярной лимфомы, мелкоклеточной лимфоцитарной лимфомы, лимфомы лимфоидной ткани слизистых оболочек, лимфомы маргинальной зоны, диффузной крупноклеточной В-клеточной лимфомы, лимфомы Беркитта и лимфомы из клеток мантийной зоны.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196184 | 2016-10-28 | ||
| EP16196184.2 | 2016-10-28 | ||
| PCT/EP2017/077654 WO2018078123A1 (en) | 2016-10-28 | 2017-10-27 | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019113370A true RU2019113370A (ru) | 2020-11-30 |
| RU2019113370A3 RU2019113370A3 (ru) | 2021-03-01 |
| RU2756405C2 RU2756405C2 (ru) | 2021-09-30 |
Family
ID=57218739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019113370A RU2756405C2 (ru) | 2016-10-28 | 2017-10-27 | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12358983B2 (ru) |
| EP (2) | EP3903821A1 (ru) |
| JP (3) | JP7094950B2 (ru) |
| KR (2) | KR20230028571A (ru) |
| CN (2) | CN118045175A (ru) |
| AU (2) | AU2017348624B2 (ru) |
| BR (1) | BR112019008244A2 (ru) |
| CA (1) | CA3037246A1 (ru) |
| CY (1) | CY1124648T1 (ru) |
| DK (1) | DK3532098T3 (ru) |
| ES (1) | ES2871574T3 (ru) |
| HR (1) | HRP20210838T1 (ru) |
| HU (1) | HUE054496T2 (ru) |
| IL (3) | IL320372A (ru) |
| LT (1) | LT3532098T (ru) |
| MX (2) | MX2019004942A (ru) |
| NZ (1) | NZ751414A (ru) |
| PL (1) | PL3532098T3 (ru) |
| PT (1) | PT3532098T (ru) |
| RS (1) | RS62036B1 (ru) |
| RU (1) | RU2756405C2 (ru) |
| SG (1) | SG10202104036QA (ru) |
| SI (1) | SI3532098T1 (ru) |
| SM (1) | SMT202100347T1 (ru) |
| WO (1) | WO2018078123A1 (ru) |
| ZA (1) | ZA201903302B (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3954388A1 (en) | 2015-08-21 | 2022-02-16 | MorphoSys AG | Combinations and uses thereof |
| PT3532098T (pt) | 2016-10-28 | 2021-06-17 | Morphosys Ag | Combinação de anticorpo anti cd19 com um inibidor bcl-2 e suas utilizações |
| FI3630177T3 (fi) | 2017-05-31 | 2023-10-18 | Morphosys Ag | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle |
| GB201809746D0 (en) * | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| CA3107085A1 (en) * | 2018-08-31 | 2020-03-05 | Adc Therapeutics Sa | Combination of anti-cd19 antibody-pyrroloenzodiazepine conjugate and ve netoclax |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CN114786723A (zh) * | 2019-10-31 | 2022-07-22 | 莫佛塞斯公司 | 序贯抗cd19疗法 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| CA2422076A1 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| EP1461423B1 (en) | 2001-12-03 | 2008-05-14 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
| DK2270050T3 (da) | 2005-12-30 | 2013-08-12 | Merck Patent Gmbh | Anti-CD19-antistoffer med nedsat immunogenicitet |
| AU2007285976B2 (en) | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
| BRPI0716661B1 (pt) | 2006-08-15 | 2019-05-21 | Hydralift Amclyde, Inc. | Aparelho e método para prover compensação de levantamento para uma carga suspensa de uma extremidade de um cabo em um ambiente marinho, com a outra extremidade do cabo. |
| CA2662340C (en) | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EA018573B1 (ru) | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| ES2599172T3 (es) | 2007-10-19 | 2017-01-31 | Seattle Genetics, Inc. | Agentes de unión a CD19 y usos de éstos |
| US20100128586A1 (en) | 2008-11-25 | 2010-05-27 | Mediatek Inc. | Method and apparatus for accessing data from disc with linking area |
| BRPI1005984A2 (pt) | 2009-02-23 | 2016-10-04 | Glenmark Pharmaceuticals Sa | anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20120128586A1 (en) | 2009-06-24 | 2012-05-24 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| US20120087915A1 (en) | 2010-06-03 | 2012-04-12 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| US8549399B2 (en) | 2011-01-18 | 2013-10-01 | Apple Inc. | Identifying a selection of content in a structured document |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| LT2744515T (lt) * | 2011-08-16 | 2022-04-25 | Morphosys Ag | Kombinuota terapija su anti-cd19 antikūnu ir azoto garstyčiomis |
| CN103703027B (zh) * | 2011-08-16 | 2018-01-12 | 莫佛塞斯公司 | 使用抗cd‑19抗体和嘌呤类似物的联合治疗 |
| KR101813830B1 (ko) * | 2013-12-05 | 2017-12-29 | 에프. 호프만-라 로슈 아게 | 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물 |
| ES2818110T3 (es) | 2014-02-28 | 2021-04-09 | Merck Sharp & Dohme | Tratamiento del cáncer con una combinación que comprende dinaciclib |
| SG11201606909RA (en) * | 2014-04-07 | 2016-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| CN106794231A (zh) | 2014-06-16 | 2017-05-31 | 赞科股份有限公司 | 用于慢性淋巴细胞性白血病（cll）的治疗 |
| JP7057669B2 (ja) | 2014-10-20 | 2022-04-20 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法において投薬するための方法および組成物 |
| SG11201705476WA (en) * | 2015-02-12 | 2017-09-28 | Seattle Genetics Inc | Combination therapy using a cd19-adc and vincristine |
| BR112017023517A2 (pt) | 2015-05-26 | 2018-07-24 | F. Hoffmann-La Roche Ag | anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20 |
| EP3302550B1 (en) | 2015-05-26 | 2019-08-28 | MorphoSys AG | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
| BR112017028530A2 (pt) | 2015-07-02 | 2018-08-28 | Celgene Corp | terapia combinada para tratamento de cânceres hematológicos e tumores sólidos |
| EP3954388A1 (en) | 2015-08-21 | 2022-02-16 | MorphoSys AG | Combinations and uses thereof |
| MD3465214T2 (ro) | 2016-05-30 | 2021-09-30 | Morphosys Ag | Metode de predicție a beneficiului terapeutic al terapiei anti-CD19 la pacienți |
| ES2874640T3 (es) | 2016-06-27 | 2021-11-05 | Morphosys Ag | Formulaciones de anticuerpos anti-CD19 |
| PT3532098T (pt) | 2016-10-28 | 2021-06-17 | Morphosys Ag | Combinação de anticorpo anti cd19 com um inibidor bcl-2 e suas utilizações |
| FI3630177T3 (fi) | 2017-05-31 | 2023-10-18 | Morphosys Ag | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle |
| US20210292410A1 (en) | 2017-12-07 | 2021-09-23 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| KR20220007087A (ko) | 2019-05-03 | 2022-01-18 | 모르포시스 아게 | 제한된 수의 nk 세포를 갖는 환자에서의 항-cd19 치료제 |
| IL292181A (en) | 2019-10-31 | 2022-06-01 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| DK4051710T3 (da) | 2019-10-31 | 2025-12-15 | Incyte Corp | Antitumor-kombinationsterapi bestående af anti-cd19-antistof og gamma-delta-t-celler |
| CN114786723A (zh) | 2019-10-31 | 2022-07-22 | 莫佛塞斯公司 | 序贯抗cd19疗法 |
| TW202216193A (zh) | 2020-06-22 | 2022-05-01 | 德商莫菲西斯公司 | 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法 |
| IL303384A (en) | 2020-12-04 | 2023-08-01 | Morphosys Ag | Anti-CD19 combination therapy |
| MX2024007649A (es) | 2021-12-22 | 2024-08-26 | Incyte Corp | Paradigma de tratamiento para una terapia con anticuerpos anti cumulo de diferenciacion (anti-cd19). |
-
2017
- 2017-10-27 PT PT177975646T patent/PT3532098T/pt unknown
- 2017-10-27 IL IL320372A patent/IL320372A/en unknown
- 2017-10-27 CA CA3037246A patent/CA3037246A1/en active Pending
- 2017-10-27 IL IL266216A patent/IL266216B2/en unknown
- 2017-10-27 BR BR112019008244-1A patent/BR112019008244A2/pt unknown
- 2017-10-27 CN CN202410183851.8A patent/CN118045175A/zh active Pending
- 2017-10-27 JP JP2019522273A patent/JP7094950B2/ja active Active
- 2017-10-27 MX MX2019004942A patent/MX2019004942A/es unknown
- 2017-10-27 HU HUE17797564A patent/HUE054496T2/hu unknown
- 2017-10-27 RU RU2019113370A patent/RU2756405C2/ru active
- 2017-10-27 PL PL17797564T patent/PL3532098T3/pl unknown
- 2017-10-27 RS RS20210792A patent/RS62036B1/sr unknown
- 2017-10-27 SI SI201730811T patent/SI3532098T1/sl unknown
- 2017-10-27 IL IL301786A patent/IL301786B2/en unknown
- 2017-10-27 US US16/342,645 patent/US12358983B2/en active Active
- 2017-10-27 DK DK17797564.6T patent/DK3532098T3/da active
- 2017-10-27 EP EP21165598.0A patent/EP3903821A1/en active Pending
- 2017-10-27 HR HRP20210838TT patent/HRP20210838T1/hr unknown
- 2017-10-27 LT LTEP17797564.6T patent/LT3532098T/lt unknown
- 2017-10-27 ES ES17797564T patent/ES2871574T3/es active Active
- 2017-10-27 NZ NZ751414A patent/NZ751414A/en unknown
- 2017-10-27 KR KR1020237005018A patent/KR20230028571A/ko not_active Ceased
- 2017-10-27 KR KR1020197012532A patent/KR102500868B1/ko active Active
- 2017-10-27 CN CN201780067047.1A patent/CN109890418B/zh active Active
- 2017-10-27 AU AU2017348624A patent/AU2017348624B2/en active Active
- 2017-10-27 SM SM20210347T patent/SMT202100347T1/it unknown
- 2017-10-27 SG SG10202104036QA patent/SG10202104036QA/en unknown
- 2017-10-27 EP EP17797564.6A patent/EP3532098B1/en active Active
- 2017-10-27 WO PCT/EP2017/077654 patent/WO2018078123A1/en not_active Ceased
-
2019
- 2019-04-26 MX MX2022016270A patent/MX2022016270A/es unknown
- 2019-05-24 ZA ZA2019/03302A patent/ZA201903302B/en unknown
-
2021
- 2021-06-10 CY CY20211100512T patent/CY1124648T1/el unknown
-
2022
- 2022-06-22 JP JP2022100006A patent/JP2022137089A/ja active Pending
-
2024
- 2024-08-01 JP JP2024125584A patent/JP2024167208A/ja active Pending
- 2024-12-23 AU AU2024287178A patent/AU2024287178A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019113370A (ru) | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения | |
| RU2017143166A (ru) | Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение | |
| RU2014103490A (ru) | Комбинированная терапия с помощью антитела к cd19 и аналога пурина | |
| RU2014103492A (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| RU2018107929A (ru) | Комбинации и их использование | |
| JP2023093495A5 (ru) | ||
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| JP2017048208A5 (ru) | ||
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| JP2022119854A5 (ru) | ||
| RU2018120695A (ru) | Связывающие молекулы, специфичные в отношении asct2, и их применения | |
| JP2019533682A5 (ru) | ||
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| HRP20210945T1 (hr) | Formulacije protutijela anti-cd19 | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| RU2015110981A (ru) | Комбинации и их применение | |
| HRP20110334T1 (hr) | PROTUTIJELA SPECIFIČNA ZA TGF-ß1 | |
| RU2013113933A (ru) | Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| JP2013542194A5 (ru) | ||
| ME02798B (me) | Protutijela protiv dkk-1" | |
| JP2019519770A5 (ru) | ||
| FI3630177T3 (fi) | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle | |
| HRP20210938T1 (hr) | Postupci za prognozu terapijske dobrobiti od anti-cd19 terapije kod pacijenata |